Lipum has finalised the clinical study report for its phase I trial of the drug candidate SOL-116, officially concluding the study. The company's largest shareholder, Flerie, played a key role in supporting the execution of the trial. To gain further insight, we spoke with Karl Elmqvist, Investment Manager at Flerie, and Ola Sandborgh, CEO of Lipum.
- The phase I results give us strong confidence as SOL-116 progresses to the next stage of development, says Karl Elmqvist.